STAT3 and hepatocellular carcinoma: Based on their activites at nM range for inhibition of STAT3 dimers, OPB-31121 and OBP-51602 are some of the most promising ones andentered clinical trials in advanced leukemias, myelodysplastic syndromes, multiple myeloma or advanced solid tumors such as hepatocellular carcinoma [151] (Figure 4E).